admin - May 2, 2011
In an April article by Michael O’Riorden in heartwire news (at theheart.org), the JUPITER trial is providing a closer understanding into cardiovascular disease prevention by showing the significant progress for those patients achieving low LDL (bad cholesterol) levels with statin therapy.
The JUPITER trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin), which began in 2003, is a study testing if the statin rosuvastatin (Crestor, AstraZeneca) would reduce heart attacks and strokes in people with normal cholesterol levels but high CRP levels.
According to the article, the trial results show that rosuvastatin worked to reduce cardiovascular events and deaths in people with LDL levels <50 mg/dL, by 64% and 46% respectively. But, most significantly, those subjects who had lower LDL levels had no increased risks of adverse events, even though the risk of new-onset diabetes did increase.
Quoted in the article is senior investigator Dr. Paul Ridker (Brigham and Women’s Hospital, Boston, MA): “What these new data from JUPITER suggest is that very low levels of LDL cholesterol can be safely achieved with aggressive statin therapy, along with diet and exercise.”
The article also cites Dr. Stephen Nissen of The Cleveland Clinic who comments that these JUPITER trial results are consistent with other statin trials.
It is the hope that physicians will see the benefits of using aggressive statin therapy along with diet, exercise, and smoking cessation to reduce LDL levels to <50 mg/dL.
Read the entire heartwire news article at http://www.theheart.org/article/1211915.do.